Patent intelligence · US
US 12338438
Conjugated oligonucleotide compounds, methods of making and uses thereof
Conjugated oligonucleotide compounds, methods of making and uses thereof
Patent details — US 12338438
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 24, 2025
- Expiration
- Jun 19, 2045
- Applicant
- E-Therapeutics PLC
- Claims
- 19
- CPC classes
- A61K, A61K47/549
Quick answer
US 12338438 (Conjugated oligonucleotide compounds, methods of making and uses thereof) is held by E-Therapeutics PLC. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- E-Therapeutics PLC
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K47/549
More from E-Therapeutics PLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12338438?
US 12338438 (Conjugated oligonucleotide compounds, methods of making and uses thereof) is held by E-Therapeutics PLC. Status: granted. Granted Jun 24, 2025. Expires Jun 19, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12338438?
E-Therapeutics PLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12338438 expire?
Our index shows an expiration date of Jun 19, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.